Skip to main content

Table 3 Risk of PCa and other-cause mortality among men on primary ADT compared to observation only

From: Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation

Time period (age)Relative risk of PCa mortality (95% CI)Relative risk of mortality due to causes other than PCa (95% CI)
ADTObservationADTObservation
1985–1994 (70–79y)1.70 (1.29–2.23)1.00 (ref)1.22 (1.00–1.49)1.00 (ref)
1995–20041.55 (1.31–1.84)1.00 (ref)1.07 (0.97–1.18)1.00 (ref)
2005–20142.71 (2.08–3.53)1.00 (ref)1.03 (0.92–1.16)1.00 (ref)
1985–1994 (>80y)1.30 (0.89–1.88)1.00 (ref)1.09 (0.85–1.39)1.00 (ref)
1995–20041.49 (1.13–1.97)1.00 (ref)1.05 (0.92–1.20)1.00 (ref)
2005–20141.65 (1.19–2.29)1.00 (ref)1.06 (0.91–1.23)1.00 (ref)
  1. p-value for age–period interaction = 0.237; p for age effect = 0.052; p for period effect = 0.005. Analysis is based on propensity matched pairs
  2. PCa prostate cancer, CI confidence interval, ADT androgen deprivation therapy, ref. reference